JPRN-UMIN000003355
Completed
Phase 2
Randomized phase II study of preoperative systemic chemotherapy of carboplatin/weekly paclitaxel followed by CEF versus weekly paclitaxel followed by CEF for operable HER2-negative breast cancer - Randomized phase II study of preoperative systemic chemotherapy of carboplatin/weekly paclitaxel followed by CEF versus weekly paclitaxel followed by CEF for operable HER2-negative breast cancer
ConditionsStage II and IIIA breast cancer
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Stage II and IIIA breast cancer
- Sponsor
- ational Cancer Center Hospital
- Enrollment
- 220
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) Patients during pregnancy or lactation 2\) Active infectious disease 3\) History of hypersensitivity for Cremophor\® EL(polyoxethylated castor oil) 4\) Interstitual pneumonia or lung fibrosis 5\) HBs antigen positive 6\) Uncontrolled diabetes
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
A trial comparing chemotherapy and bevacizumab or lapatinib with chemotherapy alone for cancer of the stomach, oesophagus or the junction of the stomach and oesophagusPatients with histologically verfied lower oesophageal, Siewert Type I, II or III oesophagogastric junction or gastric adenocarcinoma.Type III or gastric tumours should be stage 1b (T1N1, T2a/bN0), II,III or stage IV (T4 N1orN2 M0). Lower oesophageal, Type I and II tumours should be stage II to stage IVa (T1N1, T2N1, T3N0-1, but not T2N0). T4 tumours are eligible if they involve the crura or invade the mediatinal pleural only.The tumour should be operableMedDRA version: 18.0Level: PTClassification code 10017758Term: Gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0Level: PTClassification code 10062878Term: Gastrooesophageal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2006-000811-12-GBMedical Research Council Clinical Trials Unit1,100
Active, not recruiting
Not Applicable
A randomised phase II study of pre-operative or peri-operative docetaxel, oxaliplatin, capecitabine (DOX) regimen in patients with locally advanced resectable gastric cancer - IRST 151.01Patient with potentially resectable adenocarcinoma of the stomachMedDRA version: 14.1Level: PTClassification code 10017758Term: Gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2010-020189-37-ITISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI
Not yet recruiting
Not Applicable
Effect of preoperative sildenafil on patients with severe pulmonary hypertension undergoing heart valve replacement.ACTRN12611000267954Richard Renew50
Active, not recruiting
Not Applicable
A randomised Phase II study of two pre-operative chemoradiotherapy regimes (oxaliplatin and capecitabine followed by radiotherapy with either oxaliplatin and capecitabine or paclitaxel and carboplatin) for resectable oesophageal cancer.Histologically confirmed operable oesophageal cancerMedDRA version: 14.1Level: LLTClassification code 10056104Term: Squamous cell carcinoma of oesophagusSystem Organ Class: 100000004864MedDRA version: 14.1Level: LLTClassification code 10056092Term: Adenocarcinoma of oesophagusSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2012-000640-10-GBVelindre NHS Trust
Recruiting
Not Applicable
Safety and efficacy of preoperative combination therapy of chemotherapy and hyperbaric oxygen therapy for resectable pancreatic cancerResectable pancreatic cancerJPRN-UMIN000049855Division of Surgery National Hospital Organization Higashi-Ohmi General Medical Center27